Related Experiment Videos

MDR1 gene expression and its clinical relevance in primary gastric carcinomas

J Wallner1, D Depisch, A Gsur

  • 1Clinic for Internal Medicine I, University of Vienna, Austria.

Cancer
|February 1, 1993
PubMed
Abstract

Insights

Multidrug resistance (MDR1) gene expression was found in 41% of gastric carcinomas, suggesting its role in clinical drug resistance. This study investigated MDR1 RNA levels in primary tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Drug resistance is a significant challenge in treating gastric carcinomas.
  • Understanding the mechanisms of multidrug resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the expression of the multidrug resistance gene 1 (MDR1) in primary gastric carcinomas.
  • To evaluate the potential role of MDR1 in clinical drug resistance of gastric cancer.

Main Methods:

  • Analysis of MDR1 RNA levels in 22 gastric carcinoma specimens using slot blot hybridization.
  • Utilized an MDR1 cDNA probe (5A) for hybridization.

Main Results:

  • MDR1 RNA was detected in 41% of gastric carcinomas, with 18% showing high expression levels.
  • MDR1 gene expression was independent of patient age, tumor location, and lymph node status.
  • MDR1 RNA expression was less frequent in advanced tumors and absent in patients with distant metastases.

Conclusions:

  • Multidrug-resistant cells are present in primary gastric carcinomas.
  • MDR1 gene expression may contribute to the clinical drug resistance observed in gastric cancer patients.

Related Concept Videos